CERRI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.520
EU - Europa 12.662
AS - Asia 9.273
SA - Sud America 1.325
Continente sconosciuto - Info sul continente non disponibili 367
AF - Africa 193
OC - Oceania 29
Totale 43.369
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.080
IT - Italia 6.309
SG - Singapore 3.009
GB - Regno Unito 2.384
CN - Cina 2.186
HK - Hong Kong 1.021
BR - Brasile 994
VN - Vietnam 971
SE - Svezia 774
DE - Germania 687
BD - Bangladesh 579
FR - Francia 510
FI - Finlandia 381
RU - Federazione Russa 371
UA - Ucraina 309
KR - Corea 250
NL - Olanda 250
TR - Turchia 246
IN - India 228
CA - Canada 206
ID - Indonesia 193
JP - Giappone 135
BG - Bulgaria 130
MX - Messico 128
AR - Argentina 105
IE - Irlanda 94
IQ - Iraq 76
PL - Polonia 65
ES - Italia 63
PK - Pakistan 62
ZA - Sudafrica 56
EC - Ecuador 51
BE - Belgio 49
CO - Colombia 44
VE - Venezuela 36
AT - Austria 35
RO - Romania 34
AE - Emirati Arabi Uniti 33
LT - Lituania 32
CL - Cile 31
CR - Costa Rica 29
MA - Marocco 28
MY - Malesia 28
CH - Svizzera 27
SA - Arabia Saudita 26
TW - Taiwan 24
EG - Egitto 23
JO - Giordania 23
PE - Perù 22
AU - Australia 20
TN - Tunisia 20
DZ - Algeria 18
IR - Iran 18
PY - Paraguay 18
UZ - Uzbekistan 18
CZ - Repubblica Ceca 17
KE - Kenya 17
AZ - Azerbaigian 16
TH - Thailandia 16
DK - Danimarca 15
JM - Giamaica 15
NP - Nepal 15
PH - Filippine 14
UY - Uruguay 14
AL - Albania 13
LV - Lettonia 13
DO - Repubblica Dominicana 12
HR - Croazia 12
HU - Ungheria 12
IL - Israele 11
RS - Serbia 10
NI - Nicaragua 9
NZ - Nuova Zelanda 9
BO - Bolivia 8
EU - Europa 8
GE - Georgia 8
SN - Senegal 8
EE - Estonia 7
HN - Honduras 7
KG - Kirghizistan 7
NO - Norvegia 7
PT - Portogallo 7
SI - Slovenia 7
SY - Repubblica araba siriana 7
GR - Grecia 6
KZ - Kazakistan 6
OM - Oman 6
BH - Bahrain 5
BY - Bielorussia 5
ET - Etiopia 5
GT - Guatemala 5
LB - Libano 5
MD - Moldavia 5
PS - Palestinian Territory 5
TT - Trinidad e Tobago 5
BB - Barbados 4
CY - Cipro 4
KH - Cambogia 4
KW - Kuwait 4
LU - Lussemburgo 4
Totale 42.938
Salva come PNG Salva come JPEG
Città #
Ashburn 2.094
Singapore 2.027
Santa Clara 1.776
Fairfield 1.689
Southend 1.635
San Jose 1.037
Hong Kong 992
Woodbridge 988
Chandler 947
Houston 755
Council Bluffs 686
Seattle 620
Wilmington 546
Cambridge 515
Hefei 514
Milan 495
Beijing 490
Dearborn 469
Ann Arbor 444
Nyköping 444
Jacksonville 428
Rome 401
London 369
New York 353
Los Angeles 285
Ho Chi Minh City 268
Helsinki 261
The Dalles 259
Hanoi 246
Modena 246
Seoul 206
Chicago 182
San Diego 181
Naples 147
Jakarta 145
Bologna 140
Dallas 140
Sofia 124
Princeton 123
Lauterbourg 117
Florence 115
Buffalo 111
Columbus 107
Eugene 105
Tokyo 103
Palermo 102
Shanghai 99
Munich 94
Izmir 93
Moscow 93
São Paulo 85
Bari 84
Orem 84
Redwood City 83
Salt Lake City 82
Phoenix 76
Catania 68
Dublin 68
Turin 67
Frankfurt am Main 65
Boardman 64
Reggio Emilia 57
Bremen 56
Montreal 55
Atlanta 52
Mexico City 50
Toronto 49
Verona 47
Da Nang 46
Genoa 42
San Francisco 42
Brooklyn 41
Brussels 40
Guangzhou 40
Warsaw 39
Chennai 38
Dong Ket 36
Cagliari 35
Elk Grove Village 35
Padova 35
Haiphong 34
Nuremberg 33
Parma 33
Denver 32
Poplar 32
Rio de Janeiro 32
Tampa 30
Miano 29
Turku 29
Baghdad 28
Manchester 28
Redondo Beach 28
Brescia 27
Falls Church 27
Lahore 27
Mumbai 27
Ankara 26
Boston 26
Mountain View 26
Norwalk 26
Totale 27.047
Salva come PNG Salva come JPEG
Nome #
INTERSTIZIOPATIA POLMONARE NON CLASSIFICABILE O SECONDARIA A CONNETTIVITE INDIFFERENZIATA. IMPORTANZA E DIFFICOLTÀ DI UNA DIAGNOSI DIFFERENZIALE. 3.885
Malattie infiltrative diffuse del polmone 1.247
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 809
Non-steroid agents for idiopathic pulmonary fibrosis 491
Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease 489
Acute exacerbation of Idiopathic Pulmonary Fibrosis: lessons learned from the Acute Respiratory Distress Syndrome 437
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 430
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 421
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 413
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 412
Effectiveness of pulmonary rehabilitation in patients with INTERSTITIAL LUNG DISEASE of different etiology: a multicenter prospective study 382
Proteomics Analysis of Formalin-Fixed Paraffine-Embedded Tissue Reveals Key Proteins Related to Lung Dysfunction in Idiopathic Pulmonary Fibrosis. 369
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 368
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 367
Morbidity and Mortality in Patients with Idiopathic Pulmonary Fibrosis Undergoing Diagnostic Surgical Lung Biopsy 367
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 360
NEW PERSPECTIVES IN DIAGNOSIS OF INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. VALIDATION STUDY OF AN ELECTRONIC STETHOSCOPE AND AD HOC SOFTWARE FOR DETECTION OF PULMONARY CRACKLES 357
Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease 354
INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. WHAT DO WE DON’T KNOW? THE LIRA STUDY (LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS) 349
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 344
Emerging drugs for idiopathic pulmonary fibrosis. 343
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 335
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 333
Serial Ultrasound Assessment of Diaphragmatic Function and Clinical Outcome in Patients with Amyotrophic Lateral Sclerosis. 332
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 332
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 330
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 329
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 328
Management of idiopathic pulmonary fibrosis. 326
Pulmonary stretch and lung mechanotransduction: Implications for progression in the fibrotic lung 324
Expression of HOXB7 in the lung of patients with idiopathic pulmonary fibrosis: a proof of concept study. 323
Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development. 323
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 322
Rifabutin for treating pulmonary tuberculosis. 319
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. 316
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 311
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 309
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 308
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 308
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 307
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 306
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 303
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 302
Fibrotic idiopathic interstitial lung disease: the molecular and cellular key players. 302
Inspiratory effort and respiratory mechanics in spontaneously breathing patients with acute exacerbation of idiopathic pulmonary fibrosis: a retrospective matched control study. 302
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 299
Pulmonary fibrosis and the many faces of UIP 297
Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature 296
Sarcoidosis: challenging diagnostic aspects of an old disease. 295
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 295
Management of Idiopathic Pulmonary Fibrosis 295
Clinical differences in sarcoidosis patients with and without lymphoma: a single-center retrospective cohort analysis. 295
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 294
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 291
AB1157 VALIDATION OF VECTOR (VELCRO CRACKLES DETECTOR) FOR THE DIAGNOSIS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH CONNECTIVE TISSUE DISEASES 289
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 286
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 284
UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE OR UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE? A CHALLENGING DIFFERENTIAL DIAGNOSIS 280
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 279
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 278
Ultrasound assessed Diaphragm Impairment is a Predictor of Outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease undergoing Non-Invasive Ventilation. 276
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 276
Real-life comparison of Pirfenidone and Nintedanib in patients with Idiopathic Pulmonary Fibrosis: a 24-month assessment. 272
The encaged lung: rapidly progressive idiopathic pleurisy. 271
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 268
Genetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning? 264
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study 264
Smoking-related interstitial lung disease 263
Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review 262
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease 261
INTERSTITIAL LUNG DISEASE IS ASSOCIATED TO INFECTIONS OF LOWER RESPIRATORY TRACT IN IMMUNOCOMPROMISED RHEUMATOID ARTHRITIS PATIENTS 257
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 256
Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis 255
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease 254
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 253
The big clinical trials in idiopathic pulmonary fibrosis. 251
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 251
Etiology and Level of Lung Derangement Do Not Affect the Beneficial Effect of Pulmonary Rehabilitation in Patients with Interstitial Lung Diseases 251
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 248
Levels Of Fibulin-1 In The Lung And Serum Are Increased In Fibrotic Interstitial Lung Disease 247
Empoyment of the ELISPOT blood test for the diagnosis of latent tuberculosis infection in dialysis patients awaiting renal transplantation 247
AB0472 PRIMARY SJOGREN SYNDROME ASSOCIATED INTERSTITIAL LUNG DISEASE: FEATURES, TREATMENT AND OUTCOME OF A MONOCENTRIC COHORT 247
Biological effects of COVID-19 on lung cancer: can we drive our decisions? 245
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 242
Challenges in idiopathic interstitial lung disease 241
Janus-faced amiodarone-induced pneumopathy 240
Impact of Mesenchymal Stromal/stem Cell Infusions on Circulating Inflammatory Biomarkers in COVID-19 Patients: Analysis of a Phase I-IIa Trial. 236
Human mucosal associated invariant T cells detect bacterially infected cells 235
Copd, pulmonary fibrosis and ilas in aging smokers: The paradox of striking different responses to the major risk factors 235
Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients 234
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 233
Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution? 232
Tubercolosi 230
Erratum: Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature (Journal of Thoracic Disease (2019) 11 (1621-1628) DOI: 10.21037/jtd.2019.03.28) 223
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases. 220
Physiological effects of lung protective ventilation in patients with lung fibrosis and usual interstitial pneumonia pattern versus primary ARDS: a matched-control study. 218
Unusual effectiveness of systemic steroids in Whipple disease. 215
Genetic testing in diffuse parenchymal lung disease 214
CHARACTERIZATION OF ANTI-MPO POSITIVE INTERSTITIAL LUNG DISEASE. CLINICAL-SEROLOGIC AND RADIOLOGIC FEATURES AND SURVIVAL 210
Usefulness of digital velcro crackles detection in identification of interstitial lung disease in patients with connective tissue diseases 208
Totale 34.782
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.249
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.249
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.425 0 0 156 210 142 187 146 156 332 226 495 375
2022/20233.613 349 340 237 313 360 424 166 381 428 144 260 211
2023/20243.644 172 201 235 342 471 373 470 407 127 145 305 396
2024/20257.344 315 177 220 503 1.353 982 670 458 755 337 667 907
2025/202613.480 870 496 975 1.429 1.881 905 1.649 717 1.299 1.206 1.175 878
2026/20271.618 496 1.054 68 0 0 0 0 0 0 0 0 0
Totale 43.369